Opinion / When Health Policy Becomes Industrial Policy
In his latest piece, Brendan Shaw casts his eye over why those drawing up health policies need to start incorporating issues of industrial policy into their long-term planning in order…
The EFPIA’s Nathalie Moll outlines the significance of Europe’s Beating Cancer Plan to cancer patients in Europe, and its potential to boost the continent’s push to catch up with the US and China on biopharmaceutical innovation. Europe’s Beating Cancer…
In his latest piece, Brendan Shaw casts his eye over why those drawing up health policies need to start incorporating issues of industrial policy into their long-term planning in order…
Singapore recently outlined its latest Research, Innovation and Enterprise (RIE) 2025 plan, with plans to invest some USD 20 billion over the next 5 years. Here, three key stakeholders from…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park explores new ways of virtual collaboration that make our lives easier while enabling us to maintain a culture of innovation…
What were your main motivations to join Ipsen as chief business officer 16 months ago? I have worked in pharma for over 28 years across France, Portugal, Germany, Switzerland, and the US. Throughout my career, I have had a strong focus on making a real difference and building something tangible, whether in marketing, international finance, or deal-making/M&A roles. When I…
Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination. Attractive conditions…
Lorenzo Ambrosini of the Agire Foundation introduces the major new innovation projects underway in the Italian-speaking Swiss canton of Ticino; the canton’s strong existing footprint in bioinformatics, AI, and computer…
Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind the establishment of these institutions,…
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term sustainability. The life sciences industry within the United States makes significant contributions to…
In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai, a USD 31.1 million investment aiming to foster and capitalise on China’s burgeoning life sciences start-up ecosystem. …
The small Italian-speaking Canton of Ticino, nestled away in Southern Switzerland, is fast developing its reputation as a life sciences hub which – if not able to compete directly with…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why…
On 25 November 2020, the European Commission adopted a Pharmaceutical Strategy for Europe with the stated aim of ensuring that “patients have access to innovative and affordable medicines” and “to…
See our Cookie Privacy Policy Here